Efficacy and Safety of Balloon Pulmonary Angioplasty for Patients With Chronic Thromboembolic Pulmonary Hypertension and Comorbid Chronic Obstructive Pulmonary Disease

1. Dartevelle P, Fadel E, Mussot S, Chapelier A, Herve P, de Perrot M,

Cerrina J, Ladurie FL, Lehouerou D, Humbert M, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004;23:637–­648.

doi: 10.1183/09031​936.04.00079704

2. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113:2011–­2020. doi:

10.1161/CIRCU​L ATIO​NAHA.105.602565

3. Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. Eur Respir Rev.

2010;19:59–­63. doi: 10.1183/09059​180.00007309

4. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T,

Tapson VF, Ghofrani HA, Jenkins DP. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1801915. doi: 10.1183/13993​

003.01915​-­2018

5. Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-­up of

patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982;81:151–­158.

doi: 10.1378/chest.81.2.151

6. Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara

H. Refined balloon pulmonary angioplasty for inoperable patients with

chronic thromboembolic pulmonary hypertension. Circ Cardiovasc

Interv. 2012;5:748–­755. doi: 10.1161/CIRCI​​NT​ERV​​EN​TIO​NS.112.971077

7. Brenot P, Jaïs X, Taniguchi Y, Garcia Alonso C, Gerardin B, Mussot

S, Mercier O, Fabre D, Parent F, Jevnikar M, et al. French experience

of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1802095. doi: 10.1183/13993​

003.02095​-­2018

8. Taniguchi Y, Jais X, Jevnikar M, Boucly A, Weatherald J, Brenot P,

Planche O, Parent F, Savale L, Fadel E, et al. Predictors of survival in

patients with not-­

operated chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2019;38:833–­842. doi: 10.1016/j.

healun.2019.04.006

9. Taniguchi Y, Matsuoka Y, Onishi H, Yanaka K, Emoto N, Nakai H, Okada

K, Hirata K. The role of balloon pulmonary angioplasty and pulmonary

endarterectomy: Is chronic thromboembolic pulmonary hypertension

still a life-­threatening disease? Int J Cardiol. 2021;326:170–­

177. doi:

10.1016/j.ijcard.2020.10.026

J Am Heart Assoc. 2023;12:e026466. DOI: 10.1161/JAHA.122.0264669

Fujii et al

Downloaded from http://ahajournals.org by on April 9, 2023

10. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM.

Global burden of COPD: systematic review and meta-­

analysis. Eur

Respir J. 2006;28:523–­532. doi: 10.1183/09031​936.06.00124605

11. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A,

Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension

and chronic obstructive pulmonary disease. Am J Respir Crit Care Med.

2005;172:189–­194. doi: 10.1164/rccm.20040​1-­0 06OC

12. Bonderman D, Wilkens H, Wakounig S, Schäfers HJ, Jansa P, Lindner

J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J.

2009;33:325–­331. doi: 10.1183/09031​936.00087608

13. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau

G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS

guidelines for the diagnosis and treatment of pulmonary hypertension:

the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European

Respiratory Society (ERS): endorsed by: association for European

Paediatric and Congenital Cardiology (AEPC), International Society for

Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–­119.

doi: 10.1093/eurhe​artj/ehv317

14. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner

GJ, Frith P, Halpin DMG, Han M, et al. Global strategy for the diagnosis,

management, and prevention of chronic obstructive lung disease: the

GOLD science committee report 2019. Eur Respir J. 2019;53:1900164.

15. Taniguchi Y, Matsubara H. Novelties in balloon pulmonary angloplasty.

Respiratory medicine and research. 2019;75:26–­

28. doi: 10.1016/j.

resmer.2019.04.004

16. Matsuoka Y, Taniguchi Y, Miwa K, Sumimoto K, Tsuboi Y, Onishi H,

Yanaka K, Emoto N, Hirata K. Assessment of oxygenation after balloon

pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2021;333:188–­194. doi:

10.1016/j.ijcard.2021.03.002

17. Tsuboi Y, Tanaka H, Nishio R, Sawa T, Terashita D, Nakayama K,

Satomi-­Kobayashi S, Sakai Y, Emoto N, Hirata KI. Associations of exercise tolerance with hemodynamic parameters for pulmonary arterial

hypertension and for chronic thromboembolic pulmonary hypertension.

J Cardiopulm Rehabil Prev. 2017;37:341–­346. doi: 10.1097/HCR.00000​

00000​0 00257

18. Metra M, Dei Cas L, Panina G, Visioli O. Exercise hyperventilation

chronic congestive heart failure, and its relation to functional capacity and hemodynamics. Am J Cardiol. 1992;70:622–­

628. doi:

10.1016/0002-­9149(92)90202​-­A

19. Ni Y, Yu Y, Dai R, Shi G. Diffusing capacity in chronic obstructive pulmonary disease assessment: a meta-­

analysis. Chron Respir Dis.

2021;18:14799731211056340. doi: 10.1177/14799​73121​1056340

20. Kamenskaya O, Loginova I, Chernyavskiy A, Edemskiy A, Lomivorotov

VV, Karaskov A. Chronic obstructive pulmonary disease in patients with

chronic thromboembolic pulmonary hypertension: prevalence and implications for surgical treatment outcome. Clin Respir J. 2018;12:2242–­

2248. doi: 10.1111/crj.12898

21. Pepke-­Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy

C, D’Armini AM, Morsolini M, Snijder R, et al. Chronic thromboembolic

pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124:1973–­1981. doi: 10.1161/CIRCU​

LATIO​NAHA.110.015008

BPA for CTEPH with COPD

22. Taniguchi Y, Miyagawa K, Nakayama K, Kinutani H, Shinke T, Okada

K, Okita Y, Hirata KI, Emoto N. Balloon pulmonary angioplasty: an

additional treatment option to improve the prognosis of patients with

chronic thromboembolic pulmonary hypertension. EuroIntervention.

2014;10:518–­525. doi: 10.4244/EIJV1​0I4A89

23. Ghofrani HA, Staehler G, Grünig E, Halank M, Mitrovic V, Unger S,

Mueck W, Frey R, Grimminger F, Schermuly RT, et al. Acute effects of

riociguat in borderline or manifest pulmonary hypertension associated

with chronic obstructive pulmonary disease. Pulm Circ. 2015;5:296–­

304. doi: 10.1086/680214

24. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, Tamm

M. A randomised, controlled trial of bosentan in severe COPD. Eur

Respir J. 2008;32:619–­628. doi: 10.1183/09031​936.00011308

25. Nakade T, Adachi H, Murata M, Oshima S. Characteristics of patients

with a relatively greater minimum VE/VCO(2) against peak VO(2)% and

impaired exercise tolerance. Eur J Appl Physiol. 2018;118:1547–­1553.

doi: 10.1007/s0042​1-­018-­3884-­1

26. Minatsuki S, Hatano M, Maki H, Takimoto E, Morita H, Komuro I.

Analysis of oxygenation in chronic thromboembolic pulmonary hypertension using dead space ratio and intrapulmonary shunt ratio. Int Heart

J. 2019;60:1137–­1141. doi: 10.1536/ihj.19-­079

27. Aoki T, Sugimura K, Nochioka K, Miura M, Tatebe S, Yamamoto S,

Yaoita N, Suzuki H, Sato H, Kozu K, et al. Effects of balloon pulmonary

angioplasty on oxygenation in patients with chronic thromboembolic

pulmonary hypertension—­importance of intrapulmonary shunt. Circ J.

2016;80:2227–­2234. doi: 10.1253/circj.CJ-­16-­0254

28. Suda R, Tanabe N, Ishida K, Kato F, Urushibara T, Sekine A, Nishimura

R, Jujo T, Sugiura T, Shigeta A, et al. Prognostic and pathophysiological

marker for patients with chronic thromboembolic pulmonary hypertension: usefulness of diffusing capacity for carbon monoxide at diagnosis.

Respirology. 2017;22:179–­186. doi: 10.1111/resp.12883

29. Taniguchi Y, Brenot P, Jais X, Garcia C, Weatherald J, Planche O, Fadel

E, Humbert M, Simonneau G. Poor subpleural perfusion predicts failure

after balloon pulmonary angioplasty for nonoperable chronic thromboembolic pulmonary hypertension. Chest. 2018;154:521–­

531. doi:

10.1016/j.chest.2018.03.059

30. Onishi H, Taniguchi Y, Matsuoka Y, Yanaka K, Izawa Y, Tsuboi Y,

Mori S, Kono A, Nakayama K, Emoto N, et al. Evaluation of microvasculopathy using dual-­

energy computed tomography in patients

with chronic thromboembolic pulmonary hypertension. Pulm Circ.

2021;11:2045894020983162. doi: 10.1177/20458​94020​983162

31. Kim NH. Group 4 pulmonary hypertension: chronic thromboembolic

pulmonary hypertension: epidemiology, pathophysiology, and treatment. Cardiol Clin. 2016;34:435–­441. doi: 10.1016/j.ccl.2016.04.011

32. Simonneau G, Torbicki A, Dorfmuller P, Kim N. The pathophysiology

of chronic thromboembolic pulmonary hypertension. Eur Respir Rev.

2017;26:160112. doi: 10.1183/16000​617.0112-­2016

33. Takei M, Kataoka M, Kawakami T, Kuwahira I, Fukuda K. Respiratory

function and oxygenation after balloon pulmonary angioplasty. Int J

Cardiol. 2016;212:190–­191. doi: 10.1016/j.ijcard.2016.03.061

34. Yanagisawa A, Naito A, Jujo-­Sanada T, Tanabe N, Ishida K, Matsumiya

G, Suda R, Kasai H, Sekine A, Sugiura T, et al. Vascular involvement

in chronic thromboembolic pulmonary hypertension is associated with

spirometry obstructive impairment. BMC Pulm Med. 2021;21:407. doi:

10.1186/s1289​0 -­021-­01779​-­x

J Am Heart Assoc. 2023;12:e026466. DOI: 10.1161/JAHA.122.02646610

...